Foundry Partners’s Collegium Pharmaceutical COLL Stock Holding History

Foundry Partners’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$483K	Buy	16,170 +8	+0%	+$244	0.03%	234
2024 Q4	$463K	Buy	16,162 +381	+2%	+$12.6K	0.02%	242
2024 Q3	$610K	Buy	15,781 +509	+3%	+$18.2K	0.03%	236
2024 Q2	$492K	Buy	+15,272	New	+$530K	0.03%	246
2023 Q3	–	Sell	-160,588	Closed	-$3.45M	–	299
2023 Q2	$3.45M	Buy	160,588 +24,108	+18%	+$547K	0.21%	138
2023 Q1	$3.27M	Buy	+136,480	New	+$3.62M	0.21%	152
2021 Q4	–	Sell	-46,230	Closed	-$913K	–	354
2021 Q3	$913K	Sell	46,230 -197,216	-81%	-$4.26M	0.03%	264
2021 Q2	$5.75M	Sell	243,446 -2,259	-0.9%	-$52.2K	0.2%	157
2021 Q1	$5.82M	Buy	+245,705	New	+$5.84M	0.19%	161

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Foundry Partners's COLL Position: Q1 2025 in Review

Foundry Partners increased its Collegium Pharmaceutical (COLL) stake by 0.05% in Q1 2025, buying an estimated $244 and bringing the position to 16,170 shares worth $483K. The position accounts for 0.03% of the portfolio, ranked #234.

Foundry Partners first reported a position in COLL in Q1 2021 and has held it in 9 quarters since. The position peaked at $5.82M in Q1 2021. 242 funds tracked by Wall St. Rank hold COLL as of Q1 2025.

Foundry Partners held 16,170 shares of Collegium Pharmaceutical worth $483K as of Q1 2025.
Foundry Partners bought 8 Collegium Pharmaceutical shares in Q1 2025, an estimated $244.
Collegium Pharmaceutical made up 0.03% of Foundry Partners's portfolio in Q1 2025, its #234 holding.
Foundry Partners first reported a position in Collegium Pharmaceutical in Q1 2021 and has held it in 9 quarters since.
Foundry Partners's Collegium Pharmaceutical position peaked at $5.82M in Q1 2021.
242 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2025.

Based on Foundry Partners's 13F filing for Q1 2025, filed 5 May 2025.